|
|
The Challenges of Reference Pricing in EuropePublished by: Decision Resources Published: May. 28, 2007 - 28 Pages Table of Contents
AbstractIn 1989, the German government introduced reference pricing as a cost-containment strategy for the pharmaceutical industry’s high prices of drugs. Now, much of Europe employs reference pricing as a means to rein in the prices of prescription drugs. Pharmaceutical companies have been forced to decide whether to cut their prices in order to match reference prices, or maintain higher prices—thereby gambling that the money lost due to lower prescribing volumes will be more than offset by the money gained by the price. Meanwhile, patients have been caught in a web of new pricing systems that may be creating a two-class system of health care.Get the Answers You Need to Shape Your Strategy: The German government recently began waiving patients’ out-of-pocket payments on thousands of pharmaceutical products. Which category of drugs could be severely disadvantaged by these waivers? In 2004, Pfi zer denounced Germany’s GBA for including patent-protected medicines in “jumbo” reference pricing groups, thereby subjecting Sortis (atorvastatin) to reference prices. What pricing strategy did Pfizer ultimately use to defend Sortis? What was the effect of Pfi zer’s strategy on Sortis’s market share? Regional governments in Italy have some discretion when deciding reimbursement terms for reference-priced medicines. Why has the Italian Drugs Agency recently expressed concern that some regions in Italy may be abusing their discretionary privilege? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||